USD
$0.00
(0.00%
)At Close (As of Oct 15, 2025)
$147.58B
Market Cap
43.67
P/E Ratio
4.72
EPS
$273.85
52 Week High
$170.43
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $14B |
Total Revenue | $24B |
Cost Of Revenue | $9.7B |
Costof Goods And Services Sold | $9.7B |
Operating Income | $5.2B |
Selling General And Administrative | $7.8B |
Research And Development | $1.6B |
Operating Expenses | $9B |
Investment Income Net | - |
Net Interest Income | -$161M |
Interest Income | $117M |
Interest Expense | $278M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.4B |
Income Before Tax | $4.6B |
Income Tax Expense | $747M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $3.9B |
Comprehensive Income Net Of Tax | - |
Ebit | $4.9B |
Ebitda | $7.3B |
Net Income | $3.9B |
Field | Value (USD) |
---|---|
Total Assets | $78B |
Total Current Assets | $9.5B |
Cash And Cash Equivalents At Carrying Value | $2.1B |
Cash And Short Term Investments | $2.1B |
Inventory | $2.3B |
Current Net Receivables | $4.4B |
Total Non Current Assets | $68B |
Property Plant Equipment | $6.1B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $19B |
Intangible Assets Excluding Goodwill | $19B |
Goodwill | $40B |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $699M |
Other Non Current Assets | - |
Total Liabilities | $28B |
Total Current Liabilities | $6.8B |
Current Accounts Payable | $1.8B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $678M |
Total Non Current Liabilities | $21B |
Capital Lease Obligations | $1.1B |
Long Term Debt | $16B |
Current Long Term Debt | $505M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $17B |
Other Current Liabilities | $3.1B |
Other Non Current Liabilities | $214M |
Total Shareholder Equity | $50B |
Treasury Stock | - |
Retained Earnings | $44B |
Common Stock | $9M |
Common Stock Shares Outstanding | $737M |
Field | Value (USD) |
---|---|
Operating Cashflow | $6.7B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2.4B |
Capital Expenditures | $1.4B |
Change In Receivables | - |
Change In Inventory | $147M |
Profit Loss | - |
Cashflow From Investment | -$2B |
Cashflow From Financing | -$8.4B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $768M |
Dividend Payout Common Stock | $768M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$6B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $3.9B |
Field | Value (USD) |
---|---|
Gross Profit | $14B |
Total Revenue | $24B |
Cost Of Revenue | $9.7B |
Costof Goods And Services Sold | $9.7B |
Operating Income | $5.2B |
Selling General And Administrative | $7.8B |
Research And Development | $1.6B |
Operating Expenses | $9B |
Investment Income Net | - |
Net Interest Income | -$161M |
Interest Income | $117M |
Interest Expense | $278M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.4B |
Income Before Tax | $4.6B |
Income Tax Expense | $747M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $3.9B |
Comprehensive Income Net Of Tax | - |
Ebit | $4.9B |
Ebitda | $7.3B |
Net Income | $3.9B |
Field | Value |
---|---|
Ex Dividend Date | 2025-09-26 |
Declaration Date | 2025-09-09 |
Record Date | 2025-09-26 |
Payment Date | 2025-10-31 |
Amount | 0.32 |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Danaher Corporation is a prominent American diversified conglomerate based in Washington, D.C., recognized for its cutting-edge innovations across multiple sectors, including Life Sciences, Diagnostics, and Environmental & Applied Solutions. The company employs advanced technologies to advance healthcare and improve efficiencies in industrial processes worldwide, demonstrating a strong commitment to enhancing patient outcomes and operational performance. With a diverse portfolio of scientific and diagnostic products, Danaher maintains a leadership position in the global market, poised for continued growth and impact across its core sectors.